Real Life Experience with Monoclonal antibody -Sotrovimab in High Risk
COVID-19 Patients: A Retrospective Study in a Lebanese Tertiary Care
Abstract: Background: Sotrovimab, a monoclonal antibody, is among the
approved therapies for coronavirus disease – 2019 (COVID-19).
Sotrovimab binds to the spike protein of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and inhibits virus attachment to
human cells. Real-life experience about the effectiveness of Sotrovimab
is limited. We aimed to evaluate the efficacy of Sotrovimab in
preventing COVID-19 hospitalizations and other patient-related outcomes
as well as the appropriateness of use in an academic hospital in
Lebanon. Methodology: In this retrospective observational study, we
included adult patients with positive test results for SARS-CoV-2 who
received intravenous (IV) Sotrovimab at the American University of
Beirut Medical Center (AUBMC) from November 2021 through March 2022. The
data collected included patient demographics and comorbidities. Primary
outcomes were hospitalization, deterioration after 24 hours, and death
due to any cause up to 60 days after the Sotrovimab infusion. Secondary
outcomes were progression to critical illness and adverse events.
Results: A total of 62 subjects received Sotrovimab infusion at our
hospital. More than 50% of the patients had a malignancy. About 77% of
the cohort belonged to Tier 1 of the National Institutes of Health (NIH)
criteria for Sotrovimab use, and 21% of the patients had clinical
deterioration 24 hours after Sotrovimab infusion. The percentage of
progression to critical disease was 9.7% and the mortality 6.5 %.
Conclusion: Sotrovimab is effective against COVID-19 infection and
prevents mortality in high-risk patients.